Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 6/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.49 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL599787 | 1.00 | GAA (0.59) | GAALMNASMN1; SMN2HTTMEN1 | |
| SCHEMBL600069 | 0.88 | GAA (0.58) | GAALMNAMAPTALDH1A1MAPK1 | |
| SCHEMBL18986533 | 0.87 | LMNA (0.55) | LMNASMN1; SMN2HTTMEN1POLB | |
| SCHEMBL3485245 | 0.83 | L3MBTL1 (0.54) | GAALMNASMN1; SMN2HTTMEN1 | |
| SCHEMBL8008989 | 0.81 | MCHR1 (0.60) | LMNASMN1; SMN2HTTMEN1POLB | |
| SCHEMBL14002193 | 0.81 | MCHR1 (0.60) | LMNASMN1; SMN2HTTMEN1POLB | |
| SCHEMBL11793398 | 0.80 | KEAP1 (0.53) | GAALMNASMN1; SMN2HTTMEN1 | |
| SCHEMBL9840847 | 0.80 | GAA (0.44) | GAALMNASMN1; SMN2HTTMEN1 | |
| SCHEMBL12875996 | 0.79 | LMNA (0.48) | LMNASMN1; SMN2HTTMEN1POLB | |
| SCHEMBL8183061 | 0.79 | MEP1B (0.65) | MEN1KMT2AKEAP1NFE2L2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785381-B2 | Oral GLP-1 formulations | EMISPHERE TECHNOLOGIES, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785381-B2 | Oral GLP-1 formulations | EMISPHERE TECHNOLOGIES, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785381-B2 | Oral GLP-1 formulations | EMISPHERE TECHNOLOGIES, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20100016229-A1 | Oral GLP-1 Formulations | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2010-01-21 | — | — | US | disclosed |
| US-20100016229-A1 | Oral GLP-1 Formulations | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2010-01-21 | — | — | US | disclosed |
| US-20100016229-A1 | Oral GLP-1 Formulations | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2010-01-21 | — | — | US | disclosed |
| US-20060286129-A1 | Oral GLP-1 formulations | EMISPHERE TECHNOLOGIES, INC. (US) | 2006-12-21 | — | — | US | disclosed |
| WO-2005062874-A2 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| US-20050147662-A1 | Compounds and compositions for delivering active agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050147662-A1 | Compounds and compositions for delivering active agents | SERPINB1, ELANE, MMP8 | GAA 75/4885LMNA 350/4885SMN1; SMN2 119/4885 |
| US-20060286129-A1 | Oral GLP-1 formulations | GLP1R, GIPR, GCGR | GAA 896/4885LMNA 3754/4885SMN1; SMN2 2949/4885 |
| US-20100016229-A1 | Oral GLP-1 Formulations | GLP1R, GIPR, GCGR | GAA 1155/4885LMNA 3528/4885SMN1; SMN2 2041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.